CD30 as a therapeutic target for lymphoma

Area of Science:

• Hematologic malignancies
• Immunotherapy
• Oncology

Background:

• Hodgkin's lymphoma (HL) and ALK(+) anaplastic large-cell lymphoma (ALCL) are often curable but can relapse after initial treatment.
• Limited therapeutic options exist for patients with refractory or relapsed CD30-positive lymphomas.
• Monoclonal antibodies (mAbs) targeting surface receptors are a growing therapeutic strategy in hematologic malignancies.

Purpose of the Study:

• To review anti-CD30 therapies for CD30-positive lymphomas.
• To critically evaluate unconjugated, engineered, and conjugated anti-CD30 mAbs.
• To discuss therapeutic challenges and advancements in treating CD30-positive lymphomas.

Main Methods:

• Review of scientific literature on anti-CD30 therapies.
• Analysis of CD30 expression and signaling pathways.
• Evaluation of various antibody-based drug delivery systems, including antibody-drug conjugates (ADCs).

Main Results:

• Unconjugated CD30 mAbs have shown limited efficacy in recurrent HL.
• CD30 targeting offers opportunities for delivering cytotoxic payloads via ADCs.
• Brentuximab vedotin (an ADC) is approved and effective for refractory/relapsed HL and ALCL.

Conclusions:

• Anti-CD30 therapies, particularly ADCs like brentuximab vedotin, represent a significant advancement in treating CD30-positive lymphomas.
• CD30's role in signaling and internalization presents both challenges and opportunities for targeted therapy.
• Further research into engineered and conjugated mAbs is crucial for optimizing treatment outcomes.